The dozens of ‘devastating, unprecedented and dangerous’ forest fires raging across Sweden are far from manufacturing and industrial centres, says Swedish Association of the Pharmaceutical Industry.
The US FDA has drawn industry attention to the potential of 3D printing and continuous manufacturing, which it says could “improve drug quality, address shortages of medicines, lower drug costs, and bring pharmaceutical manufacturing back to the US”.
AcuraStem has received $3.7m to develop a small molecule treatment for amyotrophic lateral sclerosis (ALS), which it says could compete with Sanofi’s Riluzole and Mitsubishi Tanabe’s Radicava.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
Catalent is set to acquire Juniper Pharmaceuticals in a $133m deal, which will provide the CDMO with a new European hub and the ability to win a larger share of early-phase development programs says exec.
Orion Contract Manufacturing will make, package, and supply Peptonic Medical’s over-the-counter VagiVital product, which is set to launch later this year.
Drugmakers can greatly profit from developing a combination drug, but must address manufacturing and regulatory challenges in the early development stage, says Pharmatech Associates.
Alcami began work on Flexion Therapeutics's ZILRETTA in the fall of 2014 and today announced that it will further support commercial supply of the product, which is approved for the treatment of OA-related knee pain.
Cambrex’s news that it will be constructing a research and development laboratory at its Italy-based site follows on the heels of its recently announced plans to begin a $5m expansion in Sweden.
Wasdell Group is investing £500k ($669k) in a new laboratory as the first phase of an expansion strategy, which includes a similar investment in Ireland "to cater for all situations after Brexit," says managing director.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
SIGA is slated to receive FDA approval for the world’s first antiviral drug to treat smallpox – a milestone not reached in isolation, but in collaboration with several CROs, government agencies, and others.
Blockchain is gaining momentum in the pharmaceutical industry, but consultant Pasi Kemppainen says he would be “cautious” to implement the technology across the entire digital supply chain.
The Centre for Process Innovation (CPI) has confirmed its role in a UK initiative to accelerate vaccine production and eliminate the need for cold-chain shipping.
Celltrion has launched Bio CDMO, its new contract development and manufacturing business and part of the company's "open innovation strategy" to expand its drug pipeline portfolio.
Alcami Corporation is set to be acquired by MDP – a private equity firm which believes the CDMO could double or triple in size as a strong brand in a highly fragmented market.
Almac Group has reported a 19% growth in revenue to £531m ($709.86m) – a first for the company as it continues to invest globally and drive a strategy of strategically entering new markets, says finance director.
Drugmakers should allow time to test packaging and implement changes if needed, before the November DSCSA deadline, says contract packaging organization.
Academic research underpins many of the early success stories in continuous manufacturing. Now, Blair Brettmann and her team are working to write another chapter by applying electrospinning and other techniques to downstream processing.
Pharmaceutical companies could learn from the start-up methodology when adopting next-gen technologies, says founding editor-in-chief of WIRED Magazine UK.
The newly-formed investment firm DORA Ventures has recapitalized Tedor Pharma, which recently completed a multi-million-dollar expansion of its manufacturing capabilities.
The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.
In a deal worth up to $538m, AstraZeneca has entered into an agreement with Luye Pharma Group for the sale and license of the rights to Seroquel and Seroquel XR in several markets.
ANI Pharmaceuticals has completed its acquisition of six generic products, related manufacturing and supply agreements, and equipment from Amneal Pharmaceuticals and Impax Laboratories.
Takeda has acquired Shire for approximately $62.11bn (£46bn) to create a Japan-headquartered biopharmaceutical company with a robust pipeline and expanded geographical footprint.
Codexis is setting up Porton Pharma Solutions with its biocatalyst technology as part of a strategic collaboration aimed at liberating potential cost reductions of up to 20%, says CEO.
